Payment overview · 2025
General Payments
$739.46
43 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Jeremy Laningham, MD
Allopathic & Osteopathic Physicians|Family Medicine · CONROE, TX · NPI 1700973682
Verified facts
What the public records show
CMS Open Payments records show Robert Jeremy Laningham, MD received $739.46 in general payments during 2025 across 43 reported records.
Dexcom, Inc. accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $291.30 | 39.4% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.44 | 20.2% | 17 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.83 | 11.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.76 | 11.2% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $77.19 | 10.4% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $30.28 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.81 | 2.0% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $10.85 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $739.46 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $291.30 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.44 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.44 | 17 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.76 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $77.19 | 3 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $61.67 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $30.28 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $10.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 554 | 179 |
| Atorvastatin Calcium | Atorvastatin Calcium | 525 | 167 |
| Gabapentin | Gabapentin | 414 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 120 |
| Losartan Potassium | Losartan Potassium | 355 | 114 |
| Lisinopril | Lisinopril | 337 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 76 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 234 | 29 |
| Omeprazole | Omeprazole | 233 | 77 |
| Liothyronine Sodium | Liothyronine Sodium | 232 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 198 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 72 |
| Simvastatin | Simvastatin | 195 | 70 |
| Furosemide | Furosemide | 191 | 71 |
| Prednisone | Prednisone | 187 | 151 |
| Sertraline Hcl | Sertraline Hcl | 181 | 63 |
| Metformin Hcl | Metformin Hcl | 178 | 61 |
| Finasteride | Finasteride | 176 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 56 |
| Tramadol Hcl | Tramadol Hcl | 164 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 39 |
| Clonazepam | Clonazepam | 119 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 38 |
| Carvedilol | Carvedilol | 108 | 36 |
| Alendronate Sodium | Alendronate Sodium | 99 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 35 |
| Trazodone Hcl | Trazodone Hcl | 94 | 35 |
| Alprazolam | Alprazolam | 93 | 27 |
| Potassium Chloride | Potassium Chloride | 91 | 40 |
| Montelukast Sodium | Montelukast Sodium | 88 | 37 |
| Ozempic | Semaglutide | 85 | 23 |
| Estradiol | Estradiol | 83 | 36 |
| Meloxicam | Meloxicam | 83 | 33 |
| Allopurinol | Allopurinol | 82 | 30 |
| Np Thyroid | Thyroid,pork | 82 | 21 |
| Metformin Hcl Er | Metformin Hcl | 79 | 26 |
| Spironolactone | Spironolactone | 79 | 29 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 32 |
| Donepezil Hcl | Donepezil Hcl | 70 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 26 |
| Trulicity | Dulaglutide | 70 | 13 |
| Lorazepam | Lorazepam | 69 | 13 |
| Pregabalin | Pregabalin | 69 | 31 |
| Temazepam | Temazepam | 69 | 13 |
| Azithromycin | Azithromycin | 66 | 55 |
| Diazepam | Diazepam | 66 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 63 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 23 |
| Atenolol | Atenolol | 56 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 20 |
| Eliquis | Apixaban | 51 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | suppressed |
| Famotidine | Famotidine | 49 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 17 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 14 |
| Valsartan | Valsartan | 43 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 16 |
| Memantine Hcl | Memantine Hcl | 41 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 40 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 13 |
| Mupirocin | Mupirocin | 38 | 21 |
| Bupropion Xl | Bupropion Hcl | 37 | 16 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 19 |
| Ondansetron Odt | Ondansetron | 36 | 16 |
| Synthroid | Levothyroxine Sodium | 36 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 12 |
| Fluconazole | Fluconazole | 34 | 13 |
| Glipizide | Glipizide | 34 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 11 |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Progesterone | Progesterone, Micronized | 33 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 15 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | 13 |
| Celecoxib | Celecoxib | 27 | 11 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 22 | 22 |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Azelastine Hcl | Azelastine Hcl | 22 | 14 |
| Nifedipine Er | Nifedipine | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 15 |
| Risperidone | Risperidone | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $739.46 · 43 records | Dexcom, Inc. | Dexcom G6 Transmitter, ETERNA, Fibroscan, INSPIRE, OTEZLA, PROCLAIM, REPATHA, SUBLOCADE, VRAYLAR, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error